Insider Transactions in Q4 2021 at Phreesia, Inc. (PHR)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2021
|
Chaim Indig Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
255,000
-19.64%
|
-
|
|
Dec 31
2021
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
137
+0.17%
|
$4,795
$35.41 P/Share
|
|
Dec 31
2021
|
Randy Rasmussen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
342
+0.44%
|
$11,970
$35.41 P/Share
|
|
Dec 31
2021
|
Michael J. Davidoff SVP, Payer Business |
BUY
Exercise of conversion of derivative security
|
Direct |
6,399
+7.16%
|
$25,596
$4.71 P/Share
|
|
Dec 09
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+3.71%
|
$100,000
$2.03 P/Share
|
|
Dec 09
2021
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.66%
|
$0
$0.84 P/Share
|
|
Nov 09
2021
|
Randy Rasmussen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,185
-8.54%
|
$524,505
$73.98 P/Share
|
|
Nov 08
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,499
-1.06%
|
$112,425
$75.12 P/Share
|
|
Nov 08
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
1,499
+1.05%
|
$5,996
$4.71 P/Share
|
|
Nov 06
2021
|
Randy Rasmussen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,862
-3.29%
|
$208,926
$73.81 P/Share
|
|
Nov 05
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
3,478
-2.42%
|
$260,850
$75.15 P/Share
|
|
Nov 05
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
3,478
+2.36%
|
$13,912
$4.71 P/Share
|
|
Nov 01
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
5,451
-1.89%
|
$381,570
$70.83 P/Share
|
|
Nov 01
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
5,451
+3.6%
|
$21,804
$4.71 P/Share
|
|
Oct 29
2021
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
124
+0.43%
|
$8,680
$70.54 P/Share
|
|
Oct 29
2021
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
124
+0.86%
|
$8,680
$70.54 P/Share
|
|
Oct 15
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
5,452
-3.74%
|
$354,380
$65.36 P/Share
|
|
Oct 15
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
5,452
+3.6%
|
$21,808
$4.71 P/Share
|
|
Oct 01
2021
|
Ramin Sayar Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,797
+39.66%
|
-
|